WO2002081491A3 - Nouveaux derives de genisteine et preparations pharmaceutiques les contenant - Google Patents

Nouveaux derives de genisteine et preparations pharmaceutiques les contenant Download PDF

Info

Publication number
WO2002081491A3
WO2002081491A3 PCT/PL2002/000029 PL0200029W WO02081491A3 WO 2002081491 A3 WO2002081491 A3 WO 2002081491A3 PL 0200029 W PL0200029 W PL 0200029W WO 02081491 A3 WO02081491 A3 WO 02081491A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen atom
aryl
same
pharmaceutical preparations
Prior art date
Application number
PCT/PL2002/000029
Other languages
English (en)
Other versions
WO2002081491A2 (fr
Inventor
Osman Achmatowicz
Grzegorz Grynkiewicz
Wieslaw Pucko
Aleksander P Mazurek
Krzysztof Polkowski
Jerzy Boryski
Wieslaw Szeja
Wieslaw Szelejewski
Adam Opolski
Gabriella Pastuch-Gawolek
Czeslaw Radzikowski
Barbara Szechner
Joanna Wietrzyk
Janusz Skierski
Ilona Wandzik
Piotr Krzeczynski
Original Assignee
Inst Farmaceutyczny
Inst Lekow
Osman Achmatowicz
Grzegorz Grynkiewicz
Wieslaw Pucko
Aleksander P Mazurek
Krzysztof Polkowski
Jerzy Boryski
Wieslaw Szeja
Wieslaw Szelejewski
Adam Opolski
Gabriella Pastuch-Gawolek
Czeslaw Radzikowski
Barbara Szechner
Joanna Wietrzyk
Janusz Skierski
Ilona Wandzik
Piotr Krzeczynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Farmaceutyczny, Inst Lekow, Osman Achmatowicz, Grzegorz Grynkiewicz, Wieslaw Pucko, Aleksander P Mazurek, Krzysztof Polkowski, Jerzy Boryski, Wieslaw Szeja, Wieslaw Szelejewski, Adam Opolski, Gabriella Pastuch-Gawolek, Czeslaw Radzikowski, Barbara Szechner, Joanna Wietrzyk, Janusz Skierski, Ilona Wandzik, Piotr Krzeczynski filed Critical Inst Farmaceutyczny
Publication of WO2002081491A2 publication Critical patent/WO2002081491A2/fr
Publication of WO2002081491A3 publication Critical patent/WO2002081491A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des dérivés de génistéine représentés par la formule 1 dans laquelle R1 et R2 sont identiques ou différents et représentent indépendamment un atome d'hydrogène, alkyle, aryle, alkyloaryle, alkylcarbonyle, arylcarbonyle, chacun des groupes mentionnés ci-dessus pouvant être substitués dans une chaîne ou un noyau par des groupes amino, nitro ou nitrile, un groupe R5(R6)R7-Si dans lequel R5, R6 et R7 sont identiques ou différents et représentent un groupe C1-6 alkyle ou aryle, mono-, di- ou oligosaccharide, un groupe hydroxy au moins du groupe saccharide pouvant être substitué par un groupe acyle, alkyle, acyloxyalkyle ou aryle identique ou différent; R3 représente un atome d'hydrogène ou un groupe -COCH3; et R4 représente un atome d'hydrogène, un groupe -SO3H, SO3- ou -NH¿2? ou -NO2. L'invention concerne également leurs sels acceptables d'un point de vue pharmaceutique, présentant une activité antiproliférative et antitumorale. L'invention concerne enfin de nouveaux dérivés et des préparations pharmaceutiques les contenant, pouvant être utilisés dans le domaine de l'oncologie clinique et/ou la chimioprévention des néoplasmes.
PCT/PL2002/000029 2001-04-09 2002-04-08 Nouveaux derives de genisteine et preparations pharmaceutiques les contenant WO2002081491A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP-346955 2001-04-09
PL346955A PL205635B1 (pl) 2001-04-09 2001-04-09 Nowe pochodne genisteiny i zawierające je środki farmaceutyczne

Publications (2)

Publication Number Publication Date
WO2002081491A2 WO2002081491A2 (fr) 2002-10-17
WO2002081491A3 true WO2002081491A3 (fr) 2004-02-26

Family

ID=20078583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2002/000029 WO2002081491A2 (fr) 2001-04-09 2002-04-08 Nouveaux derives de genisteine et preparations pharmaceutiques les contenant

Country Status (2)

Country Link
PL (1) PL205635B1 (fr)
WO (1) WO2002081491A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1285586C (zh) * 2003-05-15 2006-11-22 成都迪康药物研究所 鸢尾苷元的异黄酮类衍生物及其制备方法和以其为有效药用成分的抗病毒药物
WO2007001348A2 (fr) * 2004-08-26 2007-01-04 The Ohio State University Research Foundation Isoflavones renfermant des heteroaryles utilisees comme inhibiteurs de l'aromatase
CN104860913B (zh) * 2008-12-11 2018-05-04 艾克赛特药品有限公司 染料木黄酮的晶型
PL399467A1 (pl) 2012-06-08 2013-12-09 3G Therapeutics Inc. Zastosowanie genisteiny do obnizania poziomu zwiazków organicznych spichrzanych w komórkach w leczeniu i/lub zapobieganiu lizosomalnych chorób spichrzeniowych (LChS)
CN104974204B (zh) * 2015-06-19 2017-12-19 武汉光谷人福生物医药有限公司 从广金钱草中提取分离黄酮氧苷类化合物单体的方法和系统
CN107652261B (zh) * 2017-09-30 2020-08-07 桂林医学院 一种毛蕊异黄酮衍生物及其合成方法
WO2023212130A1 (fr) * 2022-04-28 2023-11-02 GreenStone Biosciences, Inc. Traitement des effets cardiovasculaires indésirables de cannabinoïdes

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029779A2 (fr) * 1996-02-16 1997-08-21 Regents Of The University Of Minnesota Conjugues de egf-genisteine pour le traitement du cancer
WO1997032872A1 (fr) * 1996-03-05 1997-09-12 Imperial College Of Science Technology And Medicine Composes comportant un groupe sulfamate
WO1998011876A1 (fr) * 1996-09-18 1998-03-26 Marigen S.A. Peresters de glycoside de bioflavonol et leur preparation en concentres et ultramicroemulsions a action pharmacologique
WO1998048790A1 (fr) * 1997-04-28 1998-11-05 Anticancer, Inc. Utilisation de la genisteine et de composes associes pour traiter certains etats lies aux hormones sexuelles
WO1999022728A1 (fr) * 1997-10-31 1999-05-14 Arch Development Corporation Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
FR2781154A1 (fr) * 1998-07-15 2000-01-21 Lafon Labor Composition therapeutique a base d'isoflavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
WO2000066576A1 (fr) * 1999-04-30 2000-11-09 G.J. Consultants Pty Ltd Metabolites d'isoflavone
WO2001017985A1 (fr) * 1999-09-03 2001-03-15 Indena S.P.A. Nouveaux derives de flavones, de xanthones et de coumarines
WO2001049281A2 (fr) * 1999-12-30 2001-07-12 Proteotech, Inc. COMPOSES AROMATIQUES POLYHYDROXYLES UTILISES DANS LE TRAITEMENT DE L"AMYLOIDOSE ET DE MALADIES CARACTERISEES PAR LA FORMATION DE FIBRES DE α-SYNUCLEINE

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029779A2 (fr) * 1996-02-16 1997-08-21 Regents Of The University Of Minnesota Conjugues de egf-genisteine pour le traitement du cancer
WO1997032872A1 (fr) * 1996-03-05 1997-09-12 Imperial College Of Science Technology And Medicine Composes comportant un groupe sulfamate
WO1998011876A1 (fr) * 1996-09-18 1998-03-26 Marigen S.A. Peresters de glycoside de bioflavonol et leur preparation en concentres et ultramicroemulsions a action pharmacologique
WO1998048790A1 (fr) * 1997-04-28 1998-11-05 Anticancer, Inc. Utilisation de la genisteine et de composes associes pour traiter certains etats lies aux hormones sexuelles
WO1999022728A1 (fr) * 1997-10-31 1999-05-14 Arch Development Corporation Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
FR2781154A1 (fr) * 1998-07-15 2000-01-21 Lafon Labor Composition therapeutique a base d'isoflavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
WO2000066576A1 (fr) * 1999-04-30 2000-11-09 G.J. Consultants Pty Ltd Metabolites d'isoflavone
WO2001017985A1 (fr) * 1999-09-03 2001-03-15 Indena S.P.A. Nouveaux derives de flavones, de xanthones et de coumarines
WO2001049281A2 (fr) * 1999-12-30 2001-07-12 Proteotech, Inc. COMPOSES AROMATIQUES POLYHYDROXYLES UTILISES DANS LE TRAITEMENT DE L"AMYLOIDOSE ET DE MALADIES CARACTERISEES PAR LA FORMATION DE FIBRES DE α-SYNUCLEINE

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
A.C.JAIN ET AL.: "A Study of Nuclear Prenylation and Allylation of Isoflavones and Synthesis of 4'-Methyl Ethers of Asajin and Warangalone.", TETRAHEDRON, vol. 26, no. 8, 1970, pages 1977 - 1988, XP001109153 *
A.C.JAIN ET AL.: "Synthesis of Alpium Isoflavone, Osajin, and Warangalone.", JOURNAL OF ORGANIC CHEMISTRY., vol. 39, no. 15, 1974, AMERICAN CHEMICAL SOCIETY. EASTON., US, pages 2215 - 2217, XP001126263, ISSN: 0022-3263 *
B.S.BAJWA ET AL.: "Synthesis of Eupatoriochromene, Encecalin, Isoevodionol, Alloptaeroxylin & Related Compounds.", INDIAN JOURNAL OF CHEMISTRY, vol. 9, 1971, pages 17 - 19, XP001126915 *
C.L.HOLDER ET AL.: "Quantification of Soy Isoflavones, Genistein and Daidzein, and Conjugates in Rat Blood Using LC/EC-MS.", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 47, no. 9, 1999, pages 3764 - 3770, XP001126265 *
CHEMICAL ABSTRACTS, vol. 132, no. 20, 15 May 2000, Columbus, Ohio, US; abstract no. 264129, "Production, isolation and structure elucidation of novel isoflavonoid compound K3-D4, K3-D5, K3-D6" XP002222414 *
CHEMICAL ABSTRACTS, vol. 57, no. 1, 7 January 1963, Columbus, Ohio, US; abstract no. 9798h, A.VIGIER ET AL.: "Hydrolsyis of delta-oxonitriles and hydrogenation of delta oxoacids." XP002222415 *
COMPT. REND., vol. 254, 1962, pages 4473 - 5 *
D.R.DOERGE ET AL.: "Analysis of Soy Isoflavone Conjugation in Vitro and in Human Blood using Liquid Chromatography-Mass Spectrometry.", DRUG METABOLISM AND DISPOSITION, vol. 28, no. 3, 2000, pages 298 - 307, XP001126264 *
DATABASE CHEMICAL ABSTRACTS Chemical Abstracts Service, Columbus; *
DATABASE CHEMICAL ABSTRACTS Chemical Abstracts Service, Ohio; *
J.BORYSKI ET AL.: "A Regioselective Synthesis of Genistein 4'-O-Ribofuranosides.", SYNTHESIS., no. 14, November 2001 (2001-11-01), GEORG THIEME VERLAG. STUTTGART., DE, pages 2170 - 2174, XP002222413, ISSN: 0039-7881 *
J.YUN ET AL.: "Differential Inhibitors Effects of Sophoricoside Analogs on Bioactivity of Several Cytokines.", LIFE SCIENCES, vol. 67, 2000, pages 2855 - 2863, XP002222411 *
K.NISHIYAMA ET AL.: "Syntheses of Isoflavones and Isoflavone Glycosides, and Their Inhibitory Activity Against Bovine Liver B-Galactosidase.", BIOSCIENCE, BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 57, no. 1, 1993, pages 107 - 114, XP001109133 *
L.FARKAS ET AL.: "About the Existence of Padmakastein and Padmakastin", TETRAHEDRON, vol. 25, no. 5, 1969, pages 1013 - 1019, XP001109134 *
L.FARKAS ET AL.: "Transacylation reactions in the flavonoid series. IV. New syntheses of 5-methylgenistein, prunetin, biochanin-A and sissotrin", ACTA CHIMICA ACADEMIAE SCIENTIARUM HUNGARICAE, vol. 60, no. 3, 1969, pages 293 - 299, XP001126906 *
LEWIS P ET AL: "SYNTHESIS OF ANTIOXIDANT ISOFLAVONE FATTY ACID ESTERS", SPECIAL PUBLICATION - ROYAL SOCIETY OF CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, LONDON, GB, vol. 240, 1999, pages 215 - 217, XP001122875, ISSN: 0260-6291 *
M.BRUM-BOUSQUET ET AL.: "Isolement et Etude du Sarothamnoside, Nouvel Heteroside d'Isoflavone de Divers Sarothamnus.", PLANTA MEDICA, vol. 43, no. 4, 1981, pages 367 - 374, XP001126912 *
P.BEDNAREK ET AL.: "Profiling Changes in Metabolism of Isoflavonoids and their Conjugates in Lupinius albus Treated with Biotic Elicitor.", PHYTOCHEMISTRY, vol. 56, no. 1, 2001, pages 77 - 85, XP001126919 *
P.T.LEWIS ET AL.: "Synthesis of Antioxidant Isoflavone Fatty Acid Esters", TETRAHEDRON, vol. 56, no. 39, 2000, pages 7805 - 7810, XP002222410 *
Q-H.MENG ET AL.: "Incorporation of Esterified Soybean Isoflavones with Antioxidant Activity into Low density Lipoprotein.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1438, 1999, pages 369 - 376, XP002222409 *
R.J.BASS ET AL.: "5-Acetoxyisoflavones and their Chloro-Derivatives.", JOURNAL OF THE CHEMICAL SOCIETY. CHEMICAL COMMUNICATIONS., no. 6, 1979, CHEMICAL SOCIETY. LETCHWORTH., GB, pages 264, XP002222412, ISSN: 0368-1769 *
S-J. LEE ET AL.: "Antiinflammatory Activity of Isoflavanoids from Peuraria Radix and Biochanin A Derivatives.", ARCHIVES OF PHARAMACAL RESEARCH, vol. 17, no. 1, 1994, pages 31 - 35, XP000886583 *
S-Y.NAMGOONG ET AL.: "Effects of Isoflavanoidson Mouse Lymphocyte Proliferation In Vitro.", ARCHIVES OF PHARMACAL RESEARCH, vol. 17, no. 4, 1994, pages 236 - 239, XP001126903 *
T.TAKEDA ET AL.: "New Isoflavone Glycosides from the Woods of Sophora Japonica", PHYTOCHEMISTRY, vol. 16, no. 5, 1977, pages 619 - 620, XP001126918 *
Y.SHIBUYA ET AL.: "New Isoflavone Glucosides from White Lupin (Lupinus albus L.)", ZEITSCHRIFT FÜR NATURFORSCHUNG, C: JOURNAL OF BIOSCIENCES, vol. 46, no. 7-8, 1991, pages 513 - 518, XP001122873 *
ZHONGGUO KANGSHENGSU ZAZHI, vol. 24, no. 4, 1999, pages 254 - 257 *

Also Published As

Publication number Publication date
PL346955A1 (en) 2002-10-21
PL205635B1 (pl) 2010-05-31
WO2002081491A2 (fr) 2002-10-17

Similar Documents

Publication Publication Date Title
WO2003013484A3 (fr) Derives n-monoacyles de o-phenylenediamines, leurs analogues heterocycliques a six elements, et leur utilisation comme agents pharmaceutiques
NO20011478L (no) Nye N-(iminometyl)aminderivater, fremgangsmåte for fremstilling derav, anvendelse som medikamenter og sammensetningerinneholdende dem
WO2003037862A1 (fr) Derives amide, et medicaments correspondants
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
ES2185635T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
EP1156045A4 (fr) Derives d'amides et compositions de medicaments
HUP0300641A2 (hu) Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
WO2003024955A3 (fr) Inhibiteurs a petites molecules de caspases
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
YU69902A (sh) Novi derivati piperazina
DE60010076D1 (de) Chinolinderivate als antibakterielle mittel
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20045486L (no) Nye forbindelser og deres anvendelse
TR200103395T2 (tr) 13-metil eritromisin türevleri.
EP0765865A4 (fr) Compose de 2-acylaminopropanol et composition medicinale
EP1243268A4 (fr) Composition medicinale
ATE344234T1 (de) Salicylamid-derivate
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
DK0992509T3 (da) Nye makrolid-derivater
WO2006036981A3 (fr) Petits modulateurs moleculaires de l'activite de cytokines
WO2000064874A3 (fr) DERIVES DE PYRIDINE HETEROSUBSTITUES INHIBITEURS DE $i(PDE 4)
DE60121431D1 (de) Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe
FI101227B1 (fi) Menetelmä farmaseuttisesti aktiivisten 4-desoksi-4-epipodofyllotoksiinijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): BA BG BR CA CZ EE GE HR HU IL IN JP KR LT LV MK MX NO RO SI SK UA US YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP